Author

C. Prieto-Garcia

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Research Focus:cancer & tumor microenvironment· 4 Approach:experimental assay· 4 Assay:proteomics· 3 Assay:bulk RNA-seq· 2 Organism:mouse· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1

Frequent Co-Authors

M. E. Diefenbacher· 5 shared M. Reissland· 5 shared O. Hartmann· 5 shared C. Schuelein-Voelk· 4 shared M. Rosenfeldt· 4 shared C. Muench· 3 shared I. Dikic· 3 shared T. Fischer· 3 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

M. E. Diefenbacher

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Stabilisation of β-Catenin-WNT signalling by USP10 in APC-truncated colorectal cancer drives cancer stemness and enables super-competitor signalling

M. Reissland, O. Hartmann, S. Tauch, C. Prieto-Garcia, C. Schulte, D. Solvie, S. Loebbert, A. C. Jacomin, M. Pesic, J. M. Bugter, C. Schuelein-Voelk, C. Fuss, N. Pahor, C. Ade, V. Buck, , M. E. Diefenbacher

This study identifies USP10 as a deubiquitylase that stabilizes β-Catenin in APC-truncated colorectal cancer, enhancing WNT signaling and cancer stemness.

bioRxiv · Feb 10, 2023 · PreprintCancer Biology

USP28 enables oncogenic transformation of respiratory cells and its inhibition potentiates molecular therapy targeting mutant EGFR, BRAF and PI3K.

C. Prieto-Garcia, O. Hartmann, M. Reissland, F. Braun, S. Bozkurt, C. T. Fuss, C. Schuelein-Voelk, A. Buchberger, M. A. Calzado, M. T. Rosenfeldt, I. Dikic, C. Muench, M. E. Diefenbacher

This study shows USP28 promotes lung cancer by stabilizing oncogenes and its inhibition enhances therapy for EGFR, BRAF, and PI3K mutant tumors.

bioRxiv · Sep 6, 2021Cancer Biology

PTEN mutant NSCLC require ATM to suppress pro-apoptotic signalling and evade radiotherapy

T. Fischer, O. Hartmann, M. Reissland, C. Prieto-Garcia, K. Klann, C. Schuelein-Voelk, B. Polat, E. Gebhard-Hartmann, M. Rosenfeldt, C. Muench, M. Flentje, M. E. Diefenbacher

This study shows PTEN-deficient NSCLC cells rely on ATM to repair radiation damage and resist therapy, and ATM inhibition synergizes with radiation in these models.

bioRxiv · Jul 24, 2021 · PreprintCancer Biology

Inhibition of USP28 overcomes Cisplatin-Resistance of Squamous Tumors by Suppression of the Fanconi Anemia Pathway.

C. Prieto-Garcia, O. Hartmann, M. Reissland, T. Fischer, C. R. Maier, M. Rosenfeldt, C. Schuelein-Voelk, K. Klann, R. Kalb, I. Dikic, C. Muench, M. E. Diefenbacher

This study identifies USP28 inhibition as a strategy to overcome cisplatin resistance in squamous cell carcinomas by suppressing the Fanconi Anemia DNA repair pathway.

bioRxiv · Sep 10, 2020Cancer Biology

The USP28-{triangleup}Np63 axis is a vulnerability of squamous tumours

C. Prieto-Garcia, O. Hartmann, M. Reissland, F. Braun, T. Fischer, S. Walz, A. Fischer, M. Calzado, A. Orian, M. Rosenfeldt, M. Eilers, M. E. Diefenbacher

This study identifies USP28 as a stabilizer of {Delta}Np63 in squamous cell carcinomas, showing that inhibiting USP28 reduces tumor growth and survival.

bioRxiv · Jun 27, 2019Cancer Biology